Aubagio is unlikely to reduce fatigue associated with Multiple Sclerosis (MS). 85% of patients with MS report fatigue and 76.6% report that fatigue has a significant impact on their lives. One study found ponesimod to be superior to Aubagio at reducing fatigue as measured by The Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis which is a patient-reported questionnaire designed to assess fatigue-related symptoms and how they affect people with MS. The investigators found that the fatigue of ponesimod patients stabilized, while that of the Aubagio patients worsened over time.

Fatigue may be a sign of liver dysfunction and you should call your doctor if you develop unexplained fatigue or your fatigue worsens, especially if you have other symptoms such as unexplained nausea, vomiting, abdominal pain, poor appetite, yellow skin, or dark urine.

Aubagio is more effective at reducing the relapse rate for MS and the risk of disability progression.

• Treatment with Aubagio significantly reduced the annualized relapse rate for MS compared to patients who received a placebo. There was a consistent reduction of the ARR noted in subgroups defined by sex, age group, prior multiple sclerosis therapy, and baseline disease activity.
• There was also a significant reduction in the risk of disability progression after approximately two years that was sustained for 12 weeks.